Literature DB >> 20070833

A comparison of three times vs. five times weekly narrowband ultraviolet B phototherapy for the treatment of chronic plaque psoriasis.

Zahra Hallaji1, Masoumeh Barzegari, Kamran Balighi, Pouria Mansoori, Arash Taheri, Parisa Mansoori.   

Abstract

BACKGROUND: Narrowband ultraviolet B (NB-UVB) phototherapy is an effective treatment for psoriasis.
OBJECTIVES: To compare the effects of three and five times weekly NB-UVB phototherapy in the treatment of chronic plaque psoriasis.
METHODS: Sixty-five patients with chronic plaque psoriasis were allocated to receive three or five times weekly NB-UVB, starting at low dose.
RESULTS: Among the patients who completed the study, clearance was achieved in 18 out of 23 patients (78%) in the three times weekly group and in 15 out of 22 patients (68%) in the five times weekly group. The difference was not statistically significant (P=0.44). No statistically significant differences were found between the two groups in the number of treatments (P=0.95), cumulative UVB dose (P=0.51), and rate of side-effects. Length of the treatment period was significantly shorter in the five times weekly group (P<0.001). At the end of treatment, the mean psoriasis area and severity index score was lower in the three times weekly group (P=0.02).
CONCLUSIONS: We recommend three times weekly NB-UVB for chronic plaque psoriasis; however, the more rapid clearance of psoriasis with five times weekly phototherapy may justify using this method in some patients.

Entities:  

Mesh:

Year:  2010        PMID: 20070833     DOI: 10.1111/j.1600-0781.2009.00473.x

Source DB:  PubMed          Journal:  Photodermatol Photoimmunol Photomed        ISSN: 0905-4383            Impact factor:   3.135


  1 in total

1.  Our Choice: study protocol for a randomized controlled trial for optimal implementation of psoriasis treatment by the integration of Chinese and western medicine.

Authors:  Xiaoying Sun; Xiaoyong Zhou; Yuegang Wei; Wenxin Yang; Ning Huang; Yangfeng Ding; Rongyi Hu; Shun Guo; Chunyan Yang; Huilan Weng; Ying Zhang; Xi Chen; Xiaojie Ding; Liu Liu; Qingfeng Yin; Ruiping Wang; Xin Li; Bin Li
Journal:  Trials       Date:  2020-03-30       Impact factor: 2.279

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.